Literature DB >> 30004674

Molecular Determinants of Substrate Specificity in Human Insulin-Degrading Enzyme.

Lazaros Stefanidis1, Nicholas D Fusco1, Samantha E Cooper2, Jillian E Smith-Carpenter2, Benjamin J Alper1.   

Abstract

Insulin-degrading enzyme (IDE) is a 110 kDa chambered zinc metalloendopeptidase that degrades insulin, amyloid β, and other intermediate-sized aggregation prone peptides that adopt β-structures. Structural studies of IDE in complex with multiple physiological substrates have suggested a role for hydrophobic and aromatic residues of the IDE active site in substrate binding and catalysis. Here, we examine functional requirements for conserved hydrophobic and aromatic IDE active site residues that are positioned within 4.5 Å of IDE-bound insulin B chain and amyloid β peptides in the reported crystal structures for the respective enzyme-substrate complexes. Charge, size, hydrophobicity, aromaticity, and other functional group requirements for substrate binding IDE active site residues were examined through mutational analysis of the recombinant human enzyme and enzyme kinetic studies conducted using native and fluorogenic derivatives of human insulin and amyloid β peptides. A functional requirement for IDE active site residues F115, A140, F141, Y150, W199, F202, F820, and Y831 was established, and specific contributions of residue charge, size, and hydrophobicity to substrate binding, specificity, and proteolysis were demonstrated. IDE mutant alleles that exhibited enhanced or diminished proteolytic activity toward insulin or amyloid β peptides and derivative substrates were identified.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30004674     DOI: 10.1021/acs.biochem.8b00474

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  3 in total

1.  Toxoplasma gondii Toxolysin 4 Contributes to Efficient Parasite Egress from Host Cells.

Authors:  My-Hang Huynh; Marijo S Roiko; Angelica O Gomes; Ellyn N Schinke; Aric J Schultz; Swati Agrawal; Christine A Oellig; Travis R Sexton; Jessica M Beauchamp; Julie Laliberté; Komagal Kannan Sivaraman; Louis B Hersh; Sheena McGowan; Vern B Carruthers
Journal:  mSphere       Date:  2021-06-30       Impact factor: 4.389

Review 2.  Insulin-Degrading Enzyme, an Under-Estimated Potential Target to Treat Cancer?

Authors:  Laetitia Lesire; Florence Leroux; Rebecca Deprez-Poulain; Benoit Deprez
Journal:  Cells       Date:  2022-04-05       Impact factor: 6.600

Review 3.  Modulation of Insulin Sensitivity by Insulin-Degrading Enzyme.

Authors:  Carlos M González-Casimiro; Beatriz Merino; Elena Casanueva-Álvarez; Tamara Postigo-Casado; Patricia Cámara-Torres; Cristina M Fernández-Díaz; Malcolm A Leissring; Irene Cózar-Castellano; Germán Perdomo
Journal:  Biomedicines       Date:  2021-01-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.